When an AI health innovator claims a 10-day early cardiac warning, as Hello Heart has demonstrated in contrast to the standard 10-year clinical risk model, and then receives recognition such as Fast Company’s 2026 “Most Innovative Companies” award, it signals a significant shift. The question for benefits leaders, however, is not merely about technological prowess or accolades. It is about whether such claims translate into tangible, verifiable outcomes, and importantly, whether the innovator is willing to stake its business model on those results.
This is where contracting terms become the ultimate litmus test. For a benefits leader evaluating a potential renewal or new partnership, the language within a contract reveals the true confidence an innovator has in its own evidence. It moves beyond the glossy presentations and into the verifiable area of shared risk and reward.
The Imperative of Outcomes-Based Contracting
Outcomes-based contracting represents a fundamental departure from traditional fee-for-service models or even engagement-based payment structures. It demands that a vendor ties its financial compensation directly to the achievement of specific, measurable clinical and economic outcomes. This approach forces a direct alignment of incentives: the vendor only succeeds financially if the program delivers on its promises for the patient population it serves.
For benefits leaders, this framework offers a critical layer of protection and assurance. It shifts the burden of proof from the buyer to the seller, compelling innovators to not only present compelling data but also to guarantee its real-world applicability. The underlying principle is straightforward: if an intervention works as claimed, the vendor should be compensated accordingly. If it does not, payment terms should reflect that shortfall. This is particularly relevant in the rapidly evolving field of healthcare AI innovation, where novel solutions often outpace traditional validation cycles.
From Evidence Claim to Payment Term
The journey from a published clinical outcome to a contractual payment term is where the rubber meets the road for AI health innovators. An innovator might publish a study in a peer-reviewed journal demonstrating a statistically significant reduction in a particular health event. That is the evidence claim. The payment term, then, is the mechanism by which the vendor agrees to be paid only if that reduction is observed within the contracted population, under real-world conditions.
Consider the emphasis placed on Cost Effectiveness in this equation. An AI solution might improve health, but if it does so at an unsustainable cost, its long-term viability for a benefits program is limited. Therefore, contracting terms often hinge on both clinical efficacy and financial return on investment. The Clinical Evidence Quality undergirding the initial claim is what makes such a term enforceable. Without strong, independently verifiable evidence, any outcomes-based contract becomes speculative. Similarly, Patient Engagement metrics are often intertwined, as even the most effective AI cannot deliver outcomes if patients do not adopt and consistently use the solution. The agencies that tend to win this kind of work understand that these three elements, cost effectiveness, clinical evidence quality, and patient engagement, are not merely features but fundamental pillars of a sustainable business model.
Leaders in Outcomes-Based Models
A recorded set of vendors demonstrates a commitment to this outcomes-based model. Omada Health, Virta Health, and Hinge Health stand out in this regard. Their recorded material consistently ties payment terms to measured results rather than solely to engagement or participation. This commitment is not a minor detail. It is a core tenet of their business strategy, reflecting a belief in their own evidence.
For Omada Health, known for its digital care programs for chronic conditions, contracting often involves metrics related to weight loss, A1c reduction, or blood pressure control, directly linking financial outcomes to clinical improvements. Virta Health, focusing on type 2 diabetes reversal, similarly frames its payment around sustained reductions in medication use and A1c levels, often with guarantees tied to these specific clinical markers. Hinge Health, a digital musculoskeletal program, frequently structures agreements around reductions in pain, surgical avoidance, and improved functional ability, demonstrating a clear line from intervention to measurable patient benefit. Analysis of outcomes-based contracts in digital health
These companies operate within a regulated context, with considerations for FDA CDRH material where applicable, ensuring their solutions meet necessary safety and efficacy standards. But beyond regulatory compliance, their contracting terms are a clear signal to benefits leaders: they are willing to put their money where their evidence is. This approach is not universally adopted, however. Many digital health solutions still rely on engagement-based payment models, which, while important, do not offer the same level of assurance regarding actual health improvements or cost savings.
What Contracting Terms Reveal to the Buyer
For benefits leaders working through a renewal or considering new partnerships, the contracting terms offer an unfiltered view into an innovator’s confidence. A contract that includes clear, measurable outcomes tied to payment demonstrates that the vendor believes its evidence claims are strong enough to withstand real-world scrutiny. It implies a significant investment in data collection, validation, and a willingness to be held accountable. This stands in stark contrast to contracts that focus solely on “per member per month” fees or engagement metrics without explicit ties to clinical or financial results.
When reviewing these terms, a benefits leader can follow a clear logical path: from the vendor’s initial evidence claim (e.g., “our solution reduces cardiac events by X%”), to the specific metrics used for payment (e.g., “payment is contingent on a Y% reduction in cardiovascular-related emergency room visits within the enrolled population”), to the methodology for measurement and verification. This traceability is paramount. It allows for a direct assessment of whether the innovator’s business model is truly aligned with the benefits program’s objectives of improving health outcomes and managing costs effectively. The instructive read is that a contracting term is checkable: a reader can follow it from evidence claim to measured result, providing a tangible basis for trust and partnership. Commonwealth Fund report on value-based care contracting
Frequently Asked Questions
What is outcomes-based contracting and why is it important for benefits leaders?
Outcomes-based contracting ties a vendor’s financial compensation directly to the achievement of specific, measurable clinical and economic outcomes. This approach is crucial for benefits leaders because it shifts the burden of proof from the buyer to the seller, compelling innovators to guarantee the real-world applicability of their claims. It ensures that the vendor only succeeds financially if the program delivers on its promises for the patient population.
What key elements should be considered in outcomes-based contracting terms for AI health solutions?
Key elements for outcomes-based contracting terms include Cost Effectiveness, Clinical Evidence Quality, and Patient Engagement metrics. An AI solution must not only improve health but do so at a sustainable cost. The initial evidence claim needs robust, independently verifiable clinical evidence, and patient engagement is vital as even effective AI cannot deliver outcomes if patients do not use the solution.
How do contracting terms reveal an innovator’s confidence in their solution?
Contracting terms reveal an innovator’s true confidence by moving beyond glossy presentations into the verifiable realm of shared risk and reward. A contract with clear, measurable outcomes tied to payment demonstrates that the vendor believes its evidence claims are robust enough to withstand real-world scrutiny. This implies a significant investment in data collection, validation, and a willingness to be held accountable for results.
Can you provide examples of companies that successfully utilize outcomes-based models?
Omada Health, Virta Health, and Hinge Health are examples of companies that demonstrate a commitment to outcomes-based models. Omada Health ties payment to metrics like weight loss and A1c reduction. Virta Health frames payment around sustained reductions in medication use and A1c levels. Hinge Health structures agreements around reductions in pain, surgical avoidance, and improved functional ability.
